Publicaciones científicas
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Thomas G Martin 1 , Philippe Moreau 2 , Saad Z Usmani 3 , Alfred Garfall 4 , María-Victoria Mateos 5 , Jesús F San-Miguel 6 , Albert Oriol 7 , Ajay K Nooka 8 , Laura Rosinol 9 , Ajai Chari 10 , Lionel Karlin 11 , Amrita Krishnan 12 , Nizar Bahlis 13 , Rakesh Popat 14 , Britta Besemer 15 , Joaquín Martínez-López 16 , Michel Delforge 17 , Danielle Trancucci 18 , Lixia Pei 18 , Rachel Kobos 18 , John Fastenau 18 , Katharine S Gries 18 , Niels W C J van de Donk 19
Introduction: Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and subsequent treatment. Therefore, consideration of the impact of treatment on HRQoL in addition to clinical outcomes is vital.
Patients and methods: In the phase I/II MajesTEC-1 (NCT03145181, NCT04557098) study, patients with RRMM who received teclistamab, an off-the-shelf, T-cell redirecting BCMA × CD3 bispecific antibody, had deep and durable responses with manageable safety. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30-item and the EuroQol 5 Dimension 5 Level descriptive questionnaire. Changes over time from baseline were measured with a repeated measures mixed-effects model. Proportions of patients with clinically meaningful improvement after starting treatment and time to clinically meaningful worsening were assessed.
Results: Compliance was maintained throughout the study. Compared with baseline, positive changes were observed for pain, global health status, and emotional functioning with treatment; other assessments were largely unchanged from baseline. Post hoc analysis showed patients with deeper clinical response generally reported improved HRQoL outcomes. Following an initial decline in HRQoL in some scales, the proportion of patients reporting clinically meaningful improvements increased, while the proportion reporting clinically meaningful worsening decreased over time. Clinically meaningful improvements in pain were reported in ≥40% of patients at most assessment time points.
Conclusions: These results complement previously reported clinical benefits and support teclistamab as a promising therapeutic option for patients with RRMM.
CITA DEL ARTÍCULO Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):194-202. doi: 10.1016/j.clml.2023.11.001. Epub 2023 Nov 14
Nuestros autores
